Bicyclo Ring System Which Is Benzimidazole (including Hydrogenated) Patents (Class 546/273.4)
-
Publication number: 20140045898Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 6, 2013Publication date: February 13, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Paul Anthony REILLY
-
Patent number: 8648201Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R7 and Y have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors and for the treatment of inflammatory diseases.Type: GrantFiled: June 17, 2010Date of Patent: February 11, 2014Assignee: MERCK PATENT GmbHInventors: Michel Calderini, Margarita Wucherer-Plietker, Ulrich Graedler, Christina Esdar
-
Publication number: 20140031317Abstract: The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.Type: ApplicationFiled: October 1, 2013Publication date: January 30, 2014Applicant: Janssen Pharmaceutica, NVInventors: Vernon C Alford, JR., James C. Lanter, Raymond A. Ng
-
Patent number: 8637676Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: June 4, 2008Date of Patent: January 28, 2014Assignee: Theravance, Inc.Inventors: Paul Allegretti, Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
-
Publication number: 20140014885Abstract: The present invention relates to a novel non-polymeric organic ionic compound comprising one ion having a functional organic group, such as a matrix group, a hole injection group, a hole transport group, an electron injection group and an electron transport group, and comprising another ion preferably being so small that it may act as a mobile ion in films containing the organic ionic compound. Furthermore, the present invention relates to a composition containing the novel organic ionic compound and another functional compound. The novel organic ionic compound or the composition may be used in organic devices as functional materials, such as matrix materials or for materials charge transport. The resulting organic devices are also object of the present invention.Type: ApplicationFiled: February 28, 2012Publication date: January 16, 2014Applicant: Merck Patent GmbHInventors: Junyou Pan, Amir Hossain Parham
-
Publication number: 20140018368Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.Type: ApplicationFiled: July 1, 2013Publication date: January 16, 2014Applicants: Genetech, Inc., Curis, Inc.Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
-
Patent number: 8609699Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.Type: GrantFiled: August 3, 2009Date of Patent: December 17, 2013Assignee: MSD K.K.Inventors: Tomoharu Iino, Masanori Asai, Akio Ohno, Seiichi Inamura, Makoto Ishikawa, Norikazu Ohtake
-
Publication number: 20130324529Abstract: The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.Type: ApplicationFiled: August 6, 2013Publication date: December 5, 2013Applicant: JANSSEN PHARMACEUTICA NVInventors: Henricus Jacobus Maria Gijsen, Michel Anna Jozef De Cleyn, Michel Surkyn, Bie Maria Pieter Verbist
-
Publication number: 20130317057Abstract: The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.Type: ApplicationFiled: July 20, 2011Publication date: November 28, 2013Inventors: Scott B. Hoyt, Min K. Park, Clare London, Yusheng Xiong, D. Jonathan Bennett, Jaiqiang Cai, Paul Ratcliffe, Andrew Cooke, Emma Carswell, John MacLean, Rohit Saxena, Bheemashankar A. Kulkarni, Archana Gupta
-
Patent number: 8592459Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: April 13, 2010Date of Patent: November 26, 2013Assignee: Novartis AGInventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
-
Publication number: 20130309191Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: November 30, 2012Publication date: November 21, 2013Inventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Van Well
-
Publication number: 20130310393Abstract: Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR3 or N; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: September 23, 2011Publication date: November 21, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Audris Huang
-
Publication number: 20130303571Abstract: The present invention relates to compounds of general formula I in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.Type: ApplicationFiled: July 15, 2013Publication date: November 14, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Roland PFAU, Kirsten ARNDT, Henri DOODS, Klaus KLINDER, Raimund KUELZER, Dimitrijs LUBRIKS, Juergen MACK, Benjamin PELCMAN, Henning PRIEPKE, Robert ROENN, Dirk STENKAMP, Edgars SUNA
-
Patent number: 8580785Abstract: Compounds of formula (I), wherein the substituents are as defined in claim (1), and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: GrantFiled: August 14, 2006Date of Patent: November 12, 2013Assignee: Syngenta Crop Protection LLCInventors: André Jeanguenat, Roger Graham Hall, Olivier Loiseleur, Stephan Trah, Patricia Durieux, Andrew Edmunds, André Stoller
-
Publication number: 20130296309Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: July 11, 2013Publication date: November 7, 2013Inventors: Sylvie Chamoin, Qi-Ying Hu, Julien Papillon
-
Publication number: 20130296376Abstract: The present invention discloses one pot process for enantioselective synthesis of single enantiomers of substituted sulphoxides 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles or said compounds in an enantiomerically enriched form.Type: ApplicationFiled: December 26, 2012Publication date: November 7, 2013Inventor: CADILA HEALTHCARE LIMITED
-
Publication number: 20130296276Abstract: The present invention provides a compound having a muscle cell or adipocyte differentiation regulating action, useful for the prophylaxis or treatment of diseases such as diabetes, obesity, dyslipidemia and the like, and the like, and having superior efficacy. The present invention provides a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof.Type: ApplicationFiled: July 14, 2011Publication date: November 7, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Osamu UJIKAWA, Kazuaki TAKAMI, Nobuyuki TAKAKURA, Nozomu SAKAI
-
Publication number: 20130296377Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: Christopher Michael ADAMS, Charles BABU, Michael Paul CAPPARELLI, Jian DING, Takeru EHARA, Keith JENDZA, Nan JI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Xue LIANG, Nello MAINOLFI, James J. POWERS, Michael H. SERRANO-WU, Chun ZHANG
-
Patent number: 8563589Abstract: Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain with benzimidazole derivatives with PPARgamma agonist activity, as well as methods for preparing medicaments used in such treatments of mammalian pain.Type: GrantFiled: July 29, 2010Date of Patent: October 22, 2013Inventors: Lillian W. Chiang, Tage Honore
-
Publication number: 20130274471Abstract: A compound for an organic photoelectric device, an organic photoelectric device including the same, and a display device including the same the compound being represented by the following Chemical Formula 1:Type: ApplicationFiled: June 12, 2013Publication date: October 17, 2013Inventors: Kyu-Yeon IN, Myeong-Soon KANG, Ho-Kuk JUNG, Nam-Soo KIM, Eui-Su KANG, Mi-Young CHAE, Jin-Seong PARK
-
Patent number: 8551988Abstract: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).Type: GrantFiled: June 14, 2010Date of Patent: October 8, 2013Assignee: Mei Pharma, Inc.Inventors: DiZhong Chen, Hong Yan Song, Eric T. Sun, Niefang Yu, Yong Zou
-
Patent number: 8546440Abstract: The present invention is concerned with novel substituted bicyclic imidazole derivatives of Formula (I) wherein R0, R1, R3, R4, X, A1, A2, A3, A4, Y1, Y2 and Y3 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said novel compound as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: December 16, 2009Date of Patent: October 1, 2013Assignee: Janssen Pharmaceuticals, Inc.Inventors: Henricus Jacobus Maria Gijsen, Gregor James MacDonald, François Paul Bischoff, Gary John Tresadern, Andrés Avelino Trabanco-Suárez, Sven Franciscus Anna Van Brandt, Didier Jean-Claude Berthelot
-
Publication number: 20130231477Abstract: This invention relates to a method of preparing a benzoimidazole derivative at high purity and high yield so as to enable the production of the benzoimidazole derivative compound as an antagonist against a vanilloid reactor-1, and particularly to a method of preparing a benzoimidazole derivative at high purity and high yield, wherein the benzoimidazole derivative is synthesized using a novel intermediate, namely, benzaldehyde, and thereby the preparation process is simple so that it can be applied to production.Type: ApplicationFiled: September 27, 2011Publication date: September 5, 2013Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.Inventors: In Woo Kim, Ji Duck Kim, Hong Chul Yoon, Hee Kyoon Yoon, Byung Goo Lee, Joon Hwan Lee, Young Mook Lim, Soo Jin Choi
-
Publication number: 20130224195Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: ApplicationFiled: April 3, 2013Publication date: August 29, 2013Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
-
Publication number: 20130217684Abstract: Disclosed are biaryl benzoimidazole derivatives. They have an inhibitory effect on calcium influx in HEK cells, thereby showing a powerful antagonistic effect on a vanilloid receptor, and further have an analgesic effect, thereby being useful for preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, stroke, bladder hypersensitivity, irritable bowel syndrome, a respiratory disorder such as cough, asthma, and chronic obstructive pulmonary disease, burning, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases.Type: ApplicationFiled: April 5, 2013Publication date: August 22, 2013Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.Inventor: Daewoong Pharmaceutical Co., Ltd.
-
Publication number: 20130202573Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: ApplicationFiled: June 15, 2011Publication date: August 8, 2013Applicant: Ardea Biosciences, Inc.Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
-
Publication number: 20130190350Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: ApplicationFiled: December 12, 2012Publication date: July 25, 2013Applicant: CURIS, INC.Inventor: Curis, Inc.
-
Publication number: 20130183384Abstract: The present invention relates to a multiple unit pellet system (MUPS) in form of a tablet containing a pharmaceutically active ingredient, characterized in that the MUPS is an optionally coated immediate release pharmaceutical dosage form for oral administration.Type: ApplicationFiled: December 17, 2012Publication date: July 18, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Karl Gerhard WAGNER, Georg BOECK, Guido RADTKE
-
Publication number: 20130172389Abstract: The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.Type: ApplicationFiled: December 27, 2012Publication date: July 4, 2013Applicant: Allegan, Inc.Inventor: Allergan, Inc.
-
Publication number: 20130164258Abstract: The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or pre-venting HCV infection in a patient.Type: ApplicationFiled: May 28, 2010Publication date: June 27, 2013Inventors: Kevin X. Chen, Anilkumar Gopinadhan Nair, Qingbei Zeng, Stuart B. Rosenblum, Joseph A. Kozlowski, F. George Njoroge
-
Publication number: 20130165423Abstract: Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.Type: ApplicationFiled: November 30, 2012Publication date: June 27, 2013Applicant: ChemoCentryx, Inc.Inventor: ChemoCentryx, Inc.
-
Patent number: 8471033Abstract: The invention relates to a process for preparing the compound of formula 1 a valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate.Type: GrantFiled: June 12, 2009Date of Patent: June 25, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Christian Filser, Wolfgang Dersch, Rainer Hamm, Arndt Hausherr, Gunter Koch, Ulrich Scholz, Georg Zerban
-
Publication number: 20130158270Abstract: An improved process for preparing dabigatran etexilate, as well as analogous compounds of formula 7, is described.Type: ApplicationFiled: February 15, 2013Publication date: June 20, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Frieder GNAD, Stefan SCHMITT, Hermann MUELLER-BOETTICHER, Helmut HEITGER, Seigfried MEINECK, Rolf DACH, Ingo HEDDESHEIMER
-
Publication number: 20130149346Abstract: The present invention relates to a pharmaceutical composition containing dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient.Type: ApplicationFiled: March 3, 2011Publication date: June 13, 2013Applicant: ratiopharm GmbH Graf-Arco-Strasse 3Inventors: Dominique Meergans, Jana Paetz
-
Patent number: 8461181Abstract: A fused heterocyclic compound of formula (1): wherein, A1 and A2 represent a nitrogen atom or the like, R1, R2, R3 and R4 represent a halogen atom or the like, R2 and R3 represent a halogen atom or the like, R5 represents a C1-C6 chain hydrocarbon group optionally substituted with one or more halogen atoms, or the like, R6 and R7 represent a C1-C4 chain hydrocarbon group substituted with one or more halogen atoms, or the like, and n represents 0 or 1, has an excellent noxious arthropod controlling effect.Type: GrantFiled: March 9, 2012Date of Patent: June 11, 2013Assignee: Sumitomo Chemical Company, Ltd.Inventors: Masaki Takahashi, Mitsuhiko Iwakoshi, Hiroshi Ikegami
-
Patent number: 8455662Abstract: Formulations are provided, comprising: a compound of Formula I, a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof; wherein the compound of Formula I is: In some embodiments, the formulations are liquids. In other embodiments, the formulations are solids. Also provided are methods of preparing such formulations.Type: GrantFiled: July 20, 2007Date of Patent: June 4, 2013Assignee: Novartis AGInventors: Ahmad Hashash, Sean Ritchie, Kangwen Lin, Peng Shen, Augustus Okhamafe, Rampurna Gullapalli
-
Publication number: 20130137648Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.Type: ApplicationFiled: January 23, 2013Publication date: May 30, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130131036Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.Type: ApplicationFiled: October 23, 2012Publication date: May 23, 2013Applicant: AbbVie Inc.Inventor: AbbVie Inc.
-
Publication number: 20130123504Abstract: Disclosed herein is a method for the production of disulfide compounds of the formula I PAC-SA-SB-R* ??(I) wherein PAC-SA is a residue of a pharmaceutically active drug a metabolite thereof or a pharmaceutically acceptable salt thereof that is covalently bonded via the sulfur atom, SA of a reduced sulfhydryl, sulfinyl, sulfonyl or sulfonamide group to the sulfur atom SB of an oxidised sulfhydryl group of a pharmacologically acceptable sulfhydryl compound in the absence of an acid. Preferably the pharmaceutically active drug is a proton pump inhibitor and the sulfhydryl compound is N-acetyl cysteine. The disulfide compounds according to the invention can be prepared either in vitro or in vivo and are stable in the acidic conditions of the stomach. Pharmaceutical compositions containing compounds of the formula I and a method for the treatment or prophylaxis of gastrointestinal disorders using compounds of the formula I are also described.Type: ApplicationFiled: January 4, 2013Publication date: May 16, 2013Applicant: JON PTY LIMITEDInventor: Jon Pty Limited
-
Publication number: 20130116441Abstract: Process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 represent H; or either R1 represents ethyl and R2 represents n-hexyloxycarbonyl that applies to industrial scale, novel intermediates useful for the preparation thereof, and processes of preparing said intermediates.Type: ApplicationFiled: July 8, 2011Publication date: May 9, 2013Applicant: ESTEVE QUIMICA, S.A.Inventors: Antoni Segade Rodríguez, Mireia Pastó Aguilà
-
Publication number: 20130116214Abstract: The present invention provides a compound having a muscle cell or adipocyte differentiation regulating action, useful for the prophylaxis or treatment of diseases such as diabetes, obesity, dyslipidemia and the like, and the like, and having superior efficacy. The present invention provides a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof.Type: ApplicationFiled: July 14, 2011Publication date: May 9, 2013Inventors: Osamu Ujikawa, Kazuaki Takami, Nobuyuki Takakura, Nozomu Sakai
-
Publication number: 20130116440Abstract: A process of preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 represent H; or either R1 represents ethyl and R2 represents n-hexyloxycarbonyl that applies to industrial scale, novel intermediates useful for the preparation thereof, and processes of preparing said intermediates.Type: ApplicationFiled: July 8, 2011Publication date: May 9, 2013Applicant: ESTEVE QUÁMICA, S.A.Inventors: Antoni Segade Rodríguez, Mireia Pastó Aguilá
-
Publication number: 20130112946Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein X1 and X2, X1 and R1 to R10 are defined as in the specification.Type: ApplicationFiled: February 29, 2012Publication date: May 9, 2013Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.Inventors: Bum-Woo Park, Yoon-Hyun Kwak, Sun-Young Lee, Chang-Ho Lee, Se-Jin Cho
-
Patent number: 8426426Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.Type: GrantFiled: April 16, 2010Date of Patent: April 23, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Yusheng Liao, Patricia Oliver-Shaffer, Dean Stamos
-
Publication number: 20130095057Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: November 30, 2012Publication date: April 18, 2013Inventor: Summit Corporation Plc
-
Patent number: 8420655Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salt thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: December 1, 2010Date of Patent: April 16, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Zhidong Chen, Ming-Hong Hao, Weimin Liu, Ho-Yin Lo, Pui Leng Loke, Chuk Chui Man, Tina Marie Morwick, Peter Allen Nemoto, Hidenori Takahashi, Heather Tye, Lifen Wu
-
Publication number: 20130090342Abstract: The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1R mediated disorders or diseases.Type: ApplicationFiled: June 16, 2011Publication date: April 11, 2013Applicant: NOVARTIS AGInventors: Frederic Berst, Pascal Furet, Andreas Marzinzik
-
Publication number: 20130084346Abstract: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.Type: ApplicationFiled: February 28, 2011Publication date: April 4, 2013Inventors: Scott Wolkenberg, James C. Barrow, Michael S. Poslusney, Scott T. Harrison, B. Wesley Trotter, James Mulhearn, Kausik K. Nanda, Peter J. Manley, Zhijian Zhao, Jeffrey W. Schubert, Nathan Kett, Amy Zartman
-
Publication number: 20130079325Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.Type: ApplicationFiled: November 14, 2012Publication date: March 28, 2013Inventors: Jennifer R. Allen, Biswas Kaustav, Frank Chavez, Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Roxanne Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
-
Publication number: 20130075706Abstract: Some substituted biaryl ring systems may be useful in light-emitting devices, such as those comprising a light-emitting diode. For example, substituted bipyridinyl or substituted phenylpyridinyl may be useful in these devices. The substituted biaryl ring system may have at least two different substituents, including one on each ring on the biaryl system. The first substituent may include optionally substituted carbazolyl, optionally substituted diphenylamine, optionally substituted diphenylaminophenyl, and optionally substituted carbazolylphenyl. The second substituent may include optionally substituted benzimidazol-2-yl, optionally substituted benzoxazol-2-yl, and an optionally substituted benzothiazol-2-yl.Type: ApplicationFiled: September 18, 2012Publication date: March 28, 2013Applicant: NITTO DENKO CORPORATIONInventor: Nitto Denko Corporation